Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Venlafaxine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 8/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 8/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Venlafaxine SCHEMBL1560692 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL10614031 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Venlafaxine SCHEMBL27838459 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Venlafaxine SCHEMBL60857 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL10616028 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| (S)-Venlafaxine SCHEMBL3644633 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| (S)-Venlafaxine SCHEMBL4512264 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Venlafaxine SCHEMBL3863025 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Venlafaxine SCHEMBL6554144 | 0.99 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Venlafaxine SCHEMBL6126163 | 0.99 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3LMNACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 41602 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-122079853-A | N-substituted indoles and other heterocyclic compounds for the treatment of brain diseases | — | 2026-05-26 | — | — | CN | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739791-A1 | A METHOD FOR DETERMINING BIOMARKER(S) PERTAINING TO MENTAL HEALTH DISORDER(S) AND BIOMARKER(S) DETERMINED THEREFROM | University of Sharjah (AE) | 2026-05-13 | — | — | EP | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| WO-2026090164-A1 | COMPOSITIONS COMPRISING ELISMETREP AND A SECOND THERAPEUTIC AGENT FOR TREATING OR PREVENTING MIGRAINE OR PAIN | KALLYOPE, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-0700289-A1 | ANTIDEPRESSANT DOSAGE FORM | ALZA CORPORATION (US) | 1996-03-13 | — | — | EP | claimed |
| EP-0687472-A2 | Potentiation of drug response by a serotonin 1A receptor antagonist | ELI LILLY AND COMPANY (US) | 1995-12-20 | — | — | EP | claimed |
| CN-1107699-A | Treatment of incontinence | LILLY CO ELI (US) | 1995-09-06 | — | — | CN | claimed |
| EP-0667150-A1 | Venlamafaxine and its analogues for inducing cognition enhancement | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-08-16 | — | — | EP | claimed |
| EP-0654264-A1 | Treatment of incontinence with venlafaxine or an aryloxy propanamine compound | ELI LILLY AND COMPANY (US) | 1995-05-24 | — | — | EP | claimed |
| EP-0639374-A2 | New treatments using phenethyl derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-02-22 | — | — | EP | claimed |
| WO-1994027589-A2 | ANTIDEPRESSANT DOSAGE FORM | ALZA CORPORATION (US) | 1994-12-08 | — | — | WO | claimed |
| EP-0112669-B1 | PHENETHYLAMINE DERIVATIVES AND INTERMEDIATES THEREFOR | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-07-29 | — | — | EP | claimed |
| US-4535186-A | CENTRAL NERVOUS SYSTEM ANTIDEPRESSANTS; VENLAFAXINE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-08-13 | — | — | US | claimed |
| EP-0112669-A2 | Phenethylamine derivatives and intermediates therefor | AMERICAN HOME PRODUCTS CORPORATION (US) | 1984-07-04 | — | — | EP | claimed |